Ocular Therapeutix announced an underwritten public offering of 6.5 million shares of its common stock, priced at $5 per share, according to a press release.
The underwriter of the offering will be granted a 30-day option to purchase up to an additional 975,000 shares on the same terms and conditions, the release said.
Net proceeds from the offering, expected is expected to gross $32.5 million, are to be used to fund the resubmission of a new drug application for Dextenza, as well as the development of OTX-TP, OTX-TIC and OTX-TKI (Read more...)
Uncategorized